This article first appeared on GuruFocus .
-
AVLAYAH Net Product Revenue:$17.8 million in Q3 2026, up nearly five-fold from $3.6 million in the first full commercial quarter; well above prior guidance of $1012 million.
-
AVLAYAH Year-to-Date Revenue:$21.4 million in 2026 year-to-date.
-
Q4 2026 Revenue Guidance:$3032 million expected for AVLAYAH, representing more than 65% growth over Q3.
-
Operating Expenses:Essentially flat in Q3 and year-to-date compared to the same period last year, despite the commercial build for the AVLAYAH launch and pipeline progress.
-
Net Income:$70.1 million in Q3 2026, primarily due to the one-time gross proceeds of $195 million from the sale of the PRV.
-
Cash Position:Approximately $1.01 billion in cash, cash equivalents, and marketable securities as of September 30, 2026.
-
Commercial Coverage:Commercial payer coverage increased from more than 50% to more than 70% of lives during the quarter; 20 state Medicaid programs now cover AVLAYAH, up from 14 last quarter.
Release Date: November 03, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
AVLAYAH generated $17.8 million in Q3 net product revenue, nearly five-fold growth from the prior quarter and well above guidance of $10-12 million.
-
Commercial coverage for AVLAYAH expanded from 50% to over 70% of commercial lives, with 20 state Medicaid programs now covering the drug and a permanent J-Code effective October 1.
-
COMPASS Phase 2/3 study completed enrollment with 65 participants, supporting potential conversion to full approval and label expansion to adults.
-
Zafinofusp alfa for Sanfilippo syndrome type A completed the pre-specified treatment duration; BLA submission planned for 2027 with strong biomarker data (80% mean CSF heparan sulfate reduction).
-
Strong balance sheet with approximately $1.01 billion in cash and equivalents, funding operations through 2028 goals; Q3 net income of $70.1 million driven by $195 million PRV sale.
Negative Points
-
Q4 revenue guidance of $30-32 million represents a step-up that may not be sustainable as a run rate, with growth expected to moderate to a steadier pace in subsequent quarters.
-
The majority of Q3 revenue came from Phase I/II patients transitioning to commercial therapy sooner than expected, pulling forward future growth rather than reflecting new patient adds.
-
BLA submission for zafinofusp alfa is dependent on manufacturing readiness (Module 3), which is the key gating factor and could delay filing.
-
COMPASS topline data not expected until first half of 2028, creating a long wait for full approval and adult label expansion.
-
Alzheimer's programs (DNL628 and DNL921) are early-stage with initial data expected in 2027; significant clinical and regulatory risk remains, and competition in the space is intensifying.
Q & A Highlights
Q: With Q3 revenue of $17.8 million far exceeding the $10-12 million guidance and Q4 guidance set at $30-32 million, how should investors think about the trajectory and the S-curve inflection point? Can you share patient or start-form metrics? A: Chief Commercial Officer Katie Peng explained that the significant jump was driven by rapidly expanding payer coverage and the faster-than-expected transition of Phase I/II patients to commercial therapy. Because these patients were already at maintenance dose, they contributed immediately to revenue. While the S-curve inflection is arriving sooner than planned, Peng cautioned that the step-up between Q3 and Q4 should not be read as a run rate, as some growth was pulled forward. She noted the company prefers to guide on revenue rather than patient metrics at this early stage, as revenue most accurately represents how the business is evolving.
Q: What is the expected impact of the permanent J-Code on Q4 revenue, and what are your expectations for the additional Phase II data for zafinofusp alfa in Q1 2027? A: Katie Peng stated that the J-Code, effective October 1, will help reimbursement processes go much more smoothly for accounts, and this has been incorporated into the Q4 guidance. Regarding zafinofusp alfa, Chief Medical Officer Peter Chin noted that the final data will include the full 20-patient cohort with additional follow-up. He highlighted that preliminary data showed an 80% mean reduction in CSF heparan sulfate with the ability to normalize, which the company believes represents the strongest biomarker data ever presented in MPS IIIA, supporting the potential for clinical benefit.
Q: For the FTD program, what percentage reduction in NFL would you want to see to seek accelerated approval, and what functional outcomes are you looking for? A: CEO Ryan Watts explained that the company extended the endpoint to one year to focus on NFL, as proximal biomarkers of lysosomal dysfunction were only modestly elevated. He noted that FTD patients have about four to five-fold elevated NFL, similar to lysosomal storage diseases. While the company has not set a specific reduction target, a "believable" reduction will be important to move forward. He also noted that ALS has used NFL as a surrogate endpoint, providing some regulatory precedent. Chief Medical Officer Peter Chin added that there are no approved therapies for FTD, and the program received orphan drug designation earlier this year.
Q: What needs to be completed before the Sanfilippo BLA submission in 2027, and when will you provide annual sales guidance for AVLAYAH? A: CEO Ryan Watts stated that the BLA package will include data from all 20 patients who have completed the 49-week portion. The timing of the filing is primarily driven by Module 3, the manufacturing piece, as Denali is manufacturing the molecule themselves at their own facility. He confirmed the plan to file in 2027, with approval timing less clear. Regarding sales guidance, Chief Commercial Officer Katie Peng noted that the company has not yet decided whether to provide annual guidance but will continue to evaluate all metrics as the launch evolves.
Q: For the A-beta program, what are your thoughts on advancing it independently versus partnering, and what biomarkers will establish differentiation for the Pompe program? A: CFO Alexander Schuth stated that Denali has the capabilities and capital (over $1 billion in cash) to advance the entire portfolio forward. While large neurodegenerative diseases are ideal long-term partnering opportunities, the current focus is on executing and generating clinical proof of concept data. Regarding Pompe, CEO Ryan Watts noted the company will look at urine Glc4 and serum creatine kinase to show a robust biomarker response in patients switching to ETV:GAA.
Q: How should we think about U.S. penetration for the 375 pediatric patients before the COMPASS adult label, and what is the target profile for new patients? A: Chief Commercial Officer Katie Peng stated that the company believes all eligible patients should be on AVLAYAH, as almost all patients have neurologic manifestations. The expectation is that AVLAYAH will become the market leader for both incident and prevalent patients, becoming the physician's choice for treating Hunter syndrome.
Q: What are your thoughts on the recent Biogen tau data, and how do you position DNL921 in the competitive Alzheimer's space? A: CEO Ryan Watts noted that while Biogen's data showed a difference in safety profile across doses, there wasn't a robust difference in tau reduction, leaving the field confused about the target level of tau reduction needed for efficacy. For DNL921, he highlighted its unique "effector function on-off switch," which minimizes hematological findings when bound to the transferrin receptor but engages FC gamma receptors for robust plaque reduction when bound to amyloid. He expects DNL921 to show more sustained brain exposure, better plaque reduction, and a better tolerability profile compared to traditional shuttle architectures. Chief Medical Officer Peter Chin added that the company is also exploring Sub-Q administration for convenience.
Q: Can you break down de novo new patient adds versus Phase I/II rollovers, and what are the similarities between the zafinofusp alfa and AVLAYAH commercializations? A: Chief Commercial Officer Katie Peng reiterated that the company shares revenue guidance as the most reliable metric. She noted that the speed from patient interest to infusion is driven by reimbursement and coverage, which is improving. She highlighted that the commercial infrastructure built for AVLAYAH will be the same infrastructure used to launch zafinofusp alfa, as the customer base is similar. The strong belief in biomarker normalization seen in the MPS II market is expected to translate to MPS IIIA, as the same physicians will likely be treating both.
Q: What are the learnings from the AVLAYAH launch that you will apply to Sanfilippo, and does Takeda's reported decline in ELAPRASE sales reflect switching dynamics? A: Chief Commercial Officer Katie Peng stated that the commercial infrastructure built for AVLAYAH will be leveraged for the zafinofusp alfa launch, as the customer base is similar. The credibility and trust built with stakeholders during the first launch are expected to accelerate the second. CEO Ryan Watts declined to comment on Takeda's reported ELAPRASE sales decline.
Q: Can you remind us of the pricing for AVLAYAH and whether any patients have discontinued treatment? A: Chief Commercial Officer Katie Peng stated the current price is $5,200 per vial, with an average 30-kilogram patient costing about $811,000
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
